Eduard Vieta

Consuming up to four cups of coffee a day is associated with an increase in telomere length in people with severe mental disorders, such as schizophrenia or bipolar disorder. Telomere length is an indicator of cellular ageing and is shorter in people with these disorders, although the causes are not clearly understood. According to the study, published in BMJ Mental Health, the effect shown is comparable to ‘a biological age five years younger’ in coffee drinkers. 

Different antidepressant drugs cause different side effects in the body, in parameters such as heart rate, blood pressure or body weight, according to a meta-analysis published by The Lancet. For example, agomelatine administration is associated with weight loss, while other molecules such as maprotiline are associated with weight gain. The research brings together 151 studies and 17 reports from the US Food and Drug Administration (FDA), including more than 58,000 people and comparing 30 antidepressant drugs with a placebo.

Until now, perceived well-being followed a U-shaped curve depending on age, declining – due to worry, stress or depression – until people reached middle age, around 50, and then rebounding into old age. With malaise, the U is inverted and we talk about the ‘unhappiness curve’, shaped like a hump. Now, research published in PLOS One with data from the US and the UK claims that this age-related malaise is declining and that there is no longer such a hump. The reason for the change is said to be the deterioration of mental health among young people, especially those under 25. The study also includes data from 44 countries between 2020 and 2025, including Spain, and confirms that the malaise no longer takes the form of a hump, but decreases with age.

An oral formulation of risperidone could be administered weekly instead of daily to treat patients with schizophrenia with the same efficacy, according to a phase III clinical trial published in The Lancet Psychiatry. The study included 83 patients in the United States.

The U.S. FDA has approved a new drug—called Cobenfy—to treat the symptoms of schizophrenia. Unlike traditional treatments, which are based on blocking the effects of dopamine, its mechanism of action simulates the effects of another neurotransmitter, acetylcholine. It is the first drug to be approved with a different mechanism of action in over 70 years.

The Lancet Psychiatry publishes the first meta-analysis of the incidence of antidepressant treatment discontinuation symptoms that includes data from more than 20,000 patients collected from 79 randomised controlled trials and observational studies. The study sought to distinguish between symptoms directly caused by medication discontinuation and other ‘non-specific’ symptoms that may be associated with patient or professional expectations (the nocebo effect). The study concludes that one in six to seven patients will experience one or more symptoms directly caused by stopping medication, and one in 35 are likely to experience severe symptoms.  

Researchers at Northwestern University in the United States have studied the effect of a temporary decrease in sleep on the mood of mice. According to their results, the animals became more hyperactive and hypersexual for a few hours. In addition, the occasional lack of sleep had an antidepressant effect that lasted for a few days and is explained by an increase in the release of dopamine. The results are published in the journal Neuron.

A commentary published last Friday in the journal Molecular Psychiatry, signed by more than 30 researchers, challenges the conclusions of the systematic review published in the same journal in July 2022, in which the authors concluded that there was no evidence that low serotonin levels cause depression. The researchers in the new paper blame the earlier study for flaws in methodology, among other weaknesses.

Procrastination in a sample of more than 3,500 students was associated with the development of both mental and physical health problems nine months later, according to a study conducted at several universities in Sweden. The results are published in the journal JAMA Network Open.

Two studies published in the journal Nature Communications have found specific characteristics in the microbiota of people with depression, including populations of different ethnicities and habits.